Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
Portfolio Pulse from
Phio Pharmaceuticals Corp. has published research on its INTASYL compound RXI-231, which shows promise in treating hyperpigmentation. The study was featured in the December 2024 issue of Clinical, Cosmetic and Investigational Dermatology.
January 02, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals has published research on its INTASYL compound RXI-231, indicating potential in treating hyperpigmentation. This development could enhance the company's product portfolio and market position.
The publication of research on RXI-231 highlights Phio's progress in developing treatments for hyperpigmentation, potentially increasing investor interest and positively impacting stock prices. The focus on a new application of their technology could expand their market reach.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100